Oncotarget

Research Papers:

Down-regulation of traditional oncomiRs in plasma of breast cancer patients

Dana Jurkovicova, Bozena Smolkova, Monika Magyerkova, Zuzana Sestakova, Viera Horvathova Kajabova, Ludovit Kulcsar, Iveta Zmetakova, Lenka Kalinkova, Tomas Krivulcik, Marian Karaba, Juraj Benca, Tatiana Sedlackova, Gabriel Minarik, Zuzana Cierna, Ludovit Danihel, Michal Mego, Miroslav Chovanec and Ivana Fridrichova _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:77369-77384. https://doi.org/10.18632/oncotarget.20484

Metrics: PDF 1397 views  |   HTML 3208 views  |   ?  


Abstract

Dana Jurkovicova1,2, Bozena Smolkova2, Monika Magyerkova1, Zuzana Sestakova2, Viera Horvathova Kajabova2, Ludovit Kulcsar1, Iveta Zmetakova2, Lenka Kalinkova2, Tomas Krivulcik2, Marian Karaba3, Juraj Benca3,4, Tatiana Sedlackova5, Gabriel Minarik5, Zuzana Cierna6, Ludovit Danihel6,7, Michal Mego8, Miroslav Chovanec2 and Ivana Fridrichova2

1KRD Molecular Technologies Ltd., Bratislava, Slovakia

2Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

3Department of Surgical Oncology, National Cancer Institute, Bratislava, Slovakia

4Medical Department of St. Elizabeth University, Bratislava, Slovakia

5Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia

6Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, University Hospital, Bratislava, Slovakia

7Pathological-Anatomical Workplace, Health Care Surveillance Authority, Bratislava, Slovakia

82nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia

Correspondence to:

Ivana Fridrichova, email: [email protected]

Keywords: miR-17/92 cluster, miR-21, miR-27a, miR-155, down-regulation of oncomiRs

Received: May 05, 2017     Accepted: July 25, 2017     Published: August 24, 2017

ABSTRACT

Deregulated expression of microRNAs has the oncogenic or tumor suppressor function in cancer. Since miRNAs in plasma are highly stable, their quantification could contribute to more precise cancer diagnosis, prognosis and therapy prediction. We have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients. We detected down-regulation of six miRNAs in patients with invasive BC compared to controls; however, only miR-20a and miR-27a down-regulations were statistically significant. Comparing miRNA expression between early and advanced stages of BC, we observed statistically significant decrease of miR-17 and miR-19a. We identified down-regulation of miR-17 and miR-20a in patients with clinical parameters of advanced BC (lymph node metastasis, tumor grade 3, circulating tumor cells, higher Ki-67-related proliferation, hormone receptor negativity and HER2 amplification), when compared to controls. Moreover, decreased level of miR-17 was found from low to high grade. Therefore, miR-17 could represent an indicator of advanced BC. Down-regulated miR-27a expression levels were observed in all clinical categories regardless of tumor progression. Hence, miR-27a could be used as a potential diagnostic marker for BC. Our data indicates that any changes in miRNA expression levels in BC patients in comparison to controls could be highly useful for cancer-associated pathology discrimination. Moreover, dynamics of miRNA expression changes could be used for BC progression monitoring.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20484